Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | Unknown | — |
The patient received first dose of RabAvert on 14-Oct-2024, second dose on 21-Oct-2024, and patient is about 30 days late for the third dose.; Case reference number US-BN-2024-002876 is a spontaneous case initially received from a pharmacist via Med Communications (reference USBAV24-3259) on 10-Dec-2024 and concerns a female patient of unknown age. The patient's medical history and concomitant medication details were not provided. On 14-Oct-2024, the patient was vaccinated with the first dose of RabAvert along with its constituent parts prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown) at an unknown dose, route or site of administration for pre-exposure prophylaxis. On 21-Oct-2024, seven days after the first dose, the patient was vaccinated with the second dose of RabAvert along with its constituent parts prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown) at an unknown dose, route or site of administration. As reported, the patient is about 30 days late for the third dose (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of initial report, it was unknown if the patient experienced any adverse event due to RabAvert. No further information was provided.; Reporter's Comments: A female patient of unknown age is about 30 days late for the third dose of RabAvert for pre-exposure prophylaxis, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to RabAvert. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unknown age is about 30 days late for the third dose of RabAvert for pre-exposure prophylaxis, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to RabAvert. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None